Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
Authors
Keywords
-
Journal
Future Oncology
Volume 9, Issue 3, Pages 451-462
Publisher
Future Medicine Ltd
Online
2013-03-08
DOI
10.2217/fon.12.196
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors
- (2015) Oncotarget
- Pilot study of a pediatric metronomic 4-drug regimen
- (2015) Nicolas André et al. Oncotarget
- Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
- (2015) Eddy Pasquier et al. Oncotarget
- Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide
- (2015) Urban Emmenegger et al. NEOPLASIA
- Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study
- (2012) Saroj Niraula et al. BREAST CANCER RESEARCH AND TREATMENT
- Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity
- (2012) Emilia Montagna et al. Clinical Breast Cancer
- Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
- (2011) O A Khan et al. BRITISH JOURNAL OF CANCER
- Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
- (2011) Nicolas Penel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer
- (2011) P. Fedele et al. EUROPEAN JOURNAL OF CANCER
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration-refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel
- (2011) Vittorio Gebbia et al. UROLOGY
- Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer
- (2010) Simon P. Gampenrieder et al. Breast Care
- Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
- (2010) N Penel et al. BRITISH JOURNAL OF CANCER
- Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy
- (2010) Amélie Lansiaux et al. INVESTIGATIONAL NEW DRUGS
- Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas
- (2010) Leandro E. Mainetti et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Quantity and clinical relevance of circulating endothelial progenitor cells in human ovarian cancer
- (2010) Yajuan Su et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines
- (2010) Claudia Bocca et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
- (2010) Viviana R. Rozados et al. ONCOLOGY RESEARCH
- Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer
- (2009) A. Fontana et al. CLINICAL CANCER RESEARCH
- Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response
- (2009) Nan Soon Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
- (2008) R Torrisi et al. BRITISH JOURNAL OF CANCER
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib
- (2008) J. Ma et al. MOLECULAR CANCER THERAPEUTICS
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now